188 related articles for article (PubMed ID: 32582960)
1. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
Cheng L; Gou L; Wei T; Zhang J
Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
[TBL] [Abstract][Full Text] [Related]
2. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
3. Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells.
Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
Mol Med Rep; 2018 Aug; 18(2):1247-1252. PubMed ID: 29845258
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
5. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.
Zhou X; Liu B; Ning Q; Xia Z; Zhong R; Zhang L; Wu L
Oncol Rep; 2021 Jan; 45(1):217-229. PubMed ID: 33200228
[TBL] [Abstract][Full Text] [Related]
6. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
[TBL] [Abstract][Full Text] [Related]
7. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
8. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
11. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
[TBL] [Abstract][Full Text] [Related]
12. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Wilson C; Nicholes K; Bustos D; Lin E; Song Q; Stephan JP; Kirkpatrick DS; Settleman J
Oncotarget; 2014 Sep; 5(17):7328-41. PubMed ID: 25193862
[TBL] [Abstract][Full Text] [Related]
13. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Liang Q; Gu WM; Huang K; Luo MY; Zou JH; Zhuang GL; Lei HM; Chen HZ; Zhu L; Zhou L; Shen Y
Acta Pharmacol Sin; 2021 Jan; 42(1):115-119. PubMed ID: 32404981
[TBL] [Abstract][Full Text] [Related]
14. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
15. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
16. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
17. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Zhang X; Liu G; Kang Y; Dong Z; Qian Q; Ma X
PLoS One; 2013; 8(3):e57692. PubMed ID: 23520479
[TBL] [Abstract][Full Text] [Related]
18. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
19. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
20. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
